Research facility expansion
The Huntsman Cancer Institute (HCI) is a part of the University of Utah campus in Salt Lake City, US. Construction of the primary children’s and families’ cancer research centre began at the institute in June 2014 as part of fourth phase of expansion. The new facility conducts cancer research on children and families, as well as develops new advanced therapeutics to improve survivorship.
Opened in June 2017, the facility doubled the research space in the HCI.
The HCI has 231,118ft² of on-site research space, state-of-the-art clinical laboratories spread over an area of 442,000ft² and an additional 12,746ft² on-site research space located at satellite locations. The new cancer research centre added an additional 220,000ft² of space to the institute in the fourth phase of expansion.
The research facility is located at Tulane Avenue in the New Orleans Medical Research District, US.
The new research centre has a six-floor building with a total floor space of 22,000ft². It extends from the existing HCI building’s south-east corner of the research wing. It is facilitated with laboratories to study various aspects of cancers that are the leading cause of death in children suffering from leukaemia, sarcoma and brain cancers.
The expansion also included the addition of a biotechnology centre, which houses the latest genetic sequencing and imaging equipment.
The estimated investment for the expansion of the research centre is approximately $173m. It was funded by the Church of Jesus Christ of Latter-day Saints, the Jon M Huntsman Family, Huntsman Cancer Foundation, Intermountain Healthcare, and the State of Utah.
The first three phases of HCI construction were completed between 1999 and October 2011. The Jon M Huntsman Research Centre, a four-storey research facility spread across 231,000ft², was completed in 1999 as part of the first phase construction. Three floors are dedicated to accommodate research laboratories and one floor for outpatient clinics.
A Cancer Specialty Hospital spread over an area of 286,000ft² was added during the second phase expansion. The hospital with 50 in-patient rooms was opened in 2004.
The third phase involved a 156,000ft² expansion in the north-east corner of the cancer hospital. It was designed by Architectural Nexus and built by Okland Construction. The expansion added a number of new features and services to the hospital. The cancer hospital now has 50 inpatient rooms, 30 outpatient rooms, four operating rooms, expanded Cancer Learning Centre and personalised medical clinics, new imaging technologies including intraoperative MRI, new centres for breast health and advanced therapeutics, and an expanded Wellness-Survivorship Center.
The construction contract of the cancer research centre was awarded to Jacobsen Construction, a company based in Utah, while Architectural Nexus provided the design.
The HCI is a six-storey building with a built-up area of 673,000ft². The first floor houses the Linda B and Robert B Wiggins Wellness and Survivorship Center, which serves the physical and emotional needs of patients, cancer survivors and other patients. The floor also includes outpatient clinics which provide cancer care in a supportive environment.
The second floor is occupied by the Wayne A. Reaud Center for Infusion and Advanced Therapeutics. The centre has 55 infusion stations and offers chemotherapy treatments.
The third floor houses introperative MRI (I-MRI), a new technology used to capture the images of tumours in the middle of the brain surgeries. The third floor also has the Cleone Peterson Eccles Center, which provides breast cancer treatment.
A bone marrow transplant (BMT) unit with 25 rooms is located in the fourth floor. The unit treats cancers such as leukaemia, lymphoma and multiple myeloma. The intensive care unit (ICU) is located in the fifth floor of the HCI building.
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…